Theracosbio Drug Patent Portfolio
Theracosbio owns 1 orange book drug protected by 6 US patents Given below is the list of Theracosbio's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8987323 | Crystalline form of benzylbenzene SGLT2 inhibitor | 14 May, 2032 | Active |
| US10533032 | Crystalline form of benzylbenzene SGLT2 inhibitor | 03 Jul, 2031 | Active |
| US10981942 | Crystalline form of benzylbenzene SGLT2 inhibitor | 13 Jun, 2031 | Active |
| US7838499 | Benzylbenzene derivatives and methods of use | 30 Jan, 2029 | Active |
| US8106021 | Benzylbenzene derivatives and methods of use | 22 Aug, 2028 | Active |
| US8802637 | Benzylbenzene derivatives and methods of use | 22 Aug, 2028 | Active |
Latest Legal Activities on Theracosbio's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Theracosbio.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Mail O.P. Petition Decision | 18 Dec, 2023 | US10533032 |
|
Email Notification
Critical
| 18 Dec, 2023 | US10533032 |
| Mail-Record Petition Decision of Granted to Make Entity Status large | 14 Dec, 2023 | US10533032 |
| Record Petition Decision of Granted to Make Entity Status large | 13 Dec, 2023 | US10533032 |
| O.P. Petition Decision | 10 Dec, 2023 | US10533032 |
| Mail O.P. Petition Decision | 30 Nov, 2023 | US8106021 |
|
Email Notification
Critical
| 30 Nov, 2023 | US8106021 |
| Mail-Record Petition Decision of Granted to Make Entity Status large | 28 Nov, 2023 | US8106021 |
| Record Petition Decision of Granted to Make Entity Status large | 27 Nov, 2023 | US8106021 |
| O.P. Petition Decision | 25 Nov, 2023 | US8106021 |
| Payment of Maintenance Fee under 1.28(c) | 07 Sep, 2023 | US8106021 |
| Payment of Maintenance Fee under 1.28(c) | 07 Sep, 2023 | US10533032 |
| Petition Entered | 07 Sep, 2023 | US10533032 |
| Petition Entered | 07 Sep, 2023 | US8106021 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 06 Sep, 2023 | US10533032 |
Theracosbio's Family Patents
Theracosbio drugs have patent protection in a total of 32 countries. It's US patent count contributes only to 14.1% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Theracosbio Drug List
Given below is the complete list of Theracosbio's drugs and the patents protecting them.
1. Brenzavvy
Brenzavvy is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8987323 | Crystalline form of benzylbenzene SGLT2 inhibitor |
14 May, 2032
(7 years from now)
| Active |
| US10533032 | Crystalline form of benzylbenzene SGLT2 inhibitor |
03 Jul, 2031
(6 years from now)
| Active |
| US10981942 | Crystalline form of benzylbenzene SGLT2 inhibitor |
13 Jun, 2031
(6 years from now)
| Active |
| US7838499 | Benzylbenzene derivatives and methods of use |
30 Jan, 2029
(4 years from now)
| Active |
| US8106021 | Benzylbenzene derivatives and methods of use |
22 Aug, 2028
(3 years from now)
| Active |
| US8802637 | Benzylbenzene derivatives and methods of use |
22 Aug, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Brenzavvy's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List